Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Ovarian or Cervical Cancer
NCT00049556Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in Cervical Cancer (CC), Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC) and 1 more, sponsored by National Cancer Institute. Primary endpoint: Reduction in phosphorylation of EGFR, AKT, and ERK in tumor biopsies at 4 weeks. Started Oct 2002; status: completed.
02
Drugs
03
Conditions
Cervical Cancer (CC)Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00049556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00049556.